List of Seebri drug patents
Seebri is owned by Novartis.
Seebri contains Glycopyrrolate.
Seebri has a total of 2 drug patents out of which 0 drug patents have expired.
Seebri was authorised for market use on 29 October, 2015.
Seebri is available in powder;inhalation dosage forms.
The generics of Seebri are possible to be released after 20 October, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(5 years from now) | |
| US8182838 | NOVARTIS | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(5 years from now) | |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 29 October, 2015
Treatment: NA
Dosage: POWDER;INHALATION
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic